Plasma- and cerebrospinal fluid-immunoreactive endothelin-1: Effects of nonpeptide endothelin receptor antagonists with diverse affinity profiles for endothelin-A and endothelin-B receptors

Journal of Cardiovascular Pharmacology

Volumn 31, Issue SUPPL. 1, 1998, Pages

  Willette, Robert N ^a   Sauermelch, Charles F ^a   Storer, Barbara L ^a   Guiney, Stephanie ^a   Luengo, Juan I ^a   Xiang, Jia Ning ^a   Elliott, John D ^a   Ohlstein, Eliot H ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Cerebrospinal fluid; Endothelin receptor antagonist; Plasma endothelin levels; Sarafotoxin 6c; SB209670; SB217242; SB234551; SB247083

Indexed keywords

3 (2 CARBOXYMETHOXY 4 METHOXYPHENYL) 1 (3,4 METHYLENEDIOXYPHENYL) 5 PROPOXY 2 INDANCARBOXYLIC ACID; BENZOFURAN DERIVATIVE; CARBOXYLIC ACID; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; ENDOTHELIN RECEPTOR; ENRASENTAN; ENZYME INHIBITOR; INDAN DERIVATIVE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROPIONIC ACID DERIVATIVE; SARAFOTOXINS S6; SB 247083; VASOCONSTRICTOR AGENT; VIPER VENOM;

ANIMAL; ARTICLE; BLOOD; CEREBROSPINAL FLUID; DOG; DRUG ANTAGONISM; INTRACEREBROVENTRICULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM;

ANIMALS; BENZOFURANS; CARBOXYLIC ACIDS; DOGS; ENDOTHELIN-1; ENZYME INHIBITORS; INDANS; INJECTIONS, INTRAVENOUS; INJECTIONS, INTRAVENTRICULAR; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; PROPIONIC ACIDS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; VASOCONSTRICTOR AGENTS; VIPER VENOMS;

EID: 0000257624     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199800001-00044     Document Type: Article

References (29)

1. Inoue A, Yanagisawa M, Kimura S, et al. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc Natl Acad Sci USA 1989;86:2863-7.
2. Arai H, Hori S, Aramori I, Ohkubo H, Nakanishi S. Cloning and expression of a cDNA encoding an endothelin receptor. Nature 1990; 348:730-2.
3. Sakurai T, Yanagisawa M, Takuwa Y, et al. Cloning of a cDNA encoding a non-isopeptide selective subtype of the endothelin receptor. Nature 1990;348:732-5.
4. Ohlstein EH, Douglas SA, Brooks DP, et al. Functions mediated by peripheral endothelin receptors. In: Ruffolo RR, ed. Endothelin receptors from the gene to the human. New York: CRC Press, 1995:109-85.
5. Karaki H, Sudjarwo SA, Hori M, et al. ETB receptor antagonist, IRL 1038, selectively inhibits the endothelin-induced endothelium-dependent vascular relaxation. Eur J Pharmacol 1993;231:371-6.
6. Jorkasky DK, Hay DWP, Freed MI. The role of endothelin in human disease: Implications and potential therpeutic intervention. In: Ruffolo RR, ed. Endothelin receptors from the gene to the human. New York: CRC Press, 1995;215-71.
7. Cody RJ, Haas GJ, Binkley PF, Capers Q, Kelley R. Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure. Circulation 1992; 85:504-9.
8. Stewart DJ, Cernacek P, Costello KB, Rouleau JL. Elevated endothelin-1 in heart failure and loss of normal response to postural change. Circulation 1992;85:510-8.
9. Allen SW, Chatfield BA, Koppenhafer SA, et al. Circulating immunoreactive endothelin-1 in children with pulmonary hypertension. Am Rev Respir Dis 1993;148:519-22.
10. Willette RN, Feuerstein GZ, Barone FC. Endothelin in the central nervous system. In: Ruffolo RR, ed. Endothelin receptors from the gene to the human. New York: CRC Press. 1995:187-214.
11. Elliott JD, Lago MA, Peishoff CA. Endothelin receptor antagonists. In: Ruffolo RR, ed. Endothelin receptors from the gene to the human. New York: CRC Press, 1995:79-107.
12. Loffler BM, Breu V, Clozel M. Effect of different endothelin receptor antagonists and of the novel non-peptide antagonist Ro. 46-2005 on endothelin levels in rat plasma. FEBS Lett 1993;333: 108-10.
13. Teerlink JR, Carteaux JP, Sprecher U, Loffler BM, Clozel M, Clozel JP. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am J Physiol 1995;268:H432-40.
14. Plumpton C, Ferro CJ, Haynes WG, Webb DJ, Davenport AP. The increase in human plasma immunoreactive endothelin but not big endothelin-1 or its C-terminal fragment induced by systemic administration of the endothelin TAK-044. Br J Pharmacol 1996; 119:311-4.
15. Willette RN, Ohlstein EH, Mitchell MP, et al. Nonpeptide endothelin receptor antagonists. VII: Attenuation of acute hypoxiainduced pulmonary hypertension in the dog. J Pharmacol Exp. Ther 1997;280:695-701.
16. Fukuroda T, Fujikawa T, Ozaki S, Ishikawa K, Yano M, Nishikibe M. Clearance of circulating ET-1 by ETB receptors in rats. Biochem Biophys Res Commun 1994;199:1461-5.
17. Weitzberg E, Ahlborg G, Lundberg JM. Long-lasting vasoconstriction and efficient regional extraction of endothelin-1 in human splanchnic and renal tissues. Biochem Biophys Res Commun 1991; 180:1298-303.
18. Ohlstein EH, Nambi P, Lago A, et al. Nonpeptide endothelin receptor antagonists. VI: Pharmacological characterization of SB 217242, a potent and highly bioavailable endothelin receptor antagonist. J Pharmacol Exp Ther 1996;276:609-15.
19. Wallenstein S, Zucker CI, Fleiss JL. Some statistical methods useful in circulation research. Circ Res 1980;47:1-9.
20. Ohlstein EH, Nambi P, Douglas et al. A rationally designed potent nonpeptide endothelin receptor antagonist. Proc Natl Acad Sci USA 1994;91:8052-6.
21. Vierhapper H, Wagner O, Waldhausl W. Effect of endothelin-1 in man. Circulation 1990;81:1415-8.
22. Hemsen A, Modin A, Wanecek M, Malmstrom RE, Weitzberg E. Effects of Ro 47-0203 and PD122080 on the plasma kinetics, receptor binding and vascular effects of endothelin in the pig. Eur J Pharmacol 1996;318:369-76.
23. Boulanger CM, Lüscher TF. Release of endothelin from the porcine aorta: inhibition by endothelium derived nitric oxide. J Clin Invest 1990;85:587-90.
24. Ohlstein EH, Storer BL. Oxyhemoglobin stimulation of endothelin production in cultured endothelial cells. J Neurosurg 1992;77: 274-8.
25. Kuchan MJ, Frangos JA. Shear stress regulates endothelin-1 release via protein kinase C and cGMP in cultured endothelial cells. Am J Physiol 1993;264:H150-6.
26. Brunner F, Doherty AM. Role of ETB receptors in local clearance of endothelin-1 in rat heart: studies with the antagonists PD 155080 and BQ-788. FEBS Lett 1996;396:238-42.
27. De Nucci G, Thomas R, D'Orleans-Juste et al. Pressor effects of circulating endothelin are limited by its removal from the pulmonary circulation and by the release of prostacyclin and endothelium-derived relaxing factor. Proc Natl Acad Sci USA 1988;85: 9797-1004.
28. Shaw SG, Barton M, d'Uscio LV, Lüscher TF. Endothelin ETA receptors are involved in the clearance of endothelin-1 but not big-endothelin. Eur Heart J 1997;18(suppl):564.
29. Frelin C, Guedin D. Why are circulating levels of endothelin-1 so low? Cardiovasc Res 1994;28:1613.